Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 28, 2026, 6:51 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 937–960 of 22,355 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: ACTIVE Clear all
Completed Not applicable Interventional Accepts healthy volunteers

Eat, Play, Sleep: A Text Message Approach to Promoting Health Behaviors for Cancer Survivors and Their Caregivers

NCT06234267
View directory record Official record
Conditions
Cancer Survivors, Neoplasms
Interventions
Eat, Play, Sleep
Behavioral
Lead sponsor
University of Arizona
Other
Eligibility
18 Years and older
Enrollment
44 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024
U.S. locations
1
States / cities
Tucson, Arizona
Source: ClinicalTrials.gov public record
Updated May 23, 2025 · Synced Oct 28, 2026, 6:51 AM EDT
Completed Phase 2 Interventional Results available

Lucinactant for Treatment of Acute Hypoxemic Respiratory Failure in Children up to Two Years Old

NCT00578734
View directory record Official record
Conditions
Acute Hypoxemic Respiratory Failure
Interventions
Lucinactant, Sham Comparator
Drug · Other
Lead sponsor
Windtree Therapeutics
Industry
Eligibility
Up to 2 Years
Enrollment
165 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
1
States / cities
Warrington, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 3, 2012 · Synced Oct 28, 2026, 6:51 AM EDT
Terminated Phase 2 Interventional

Personalized Active Immunotherapy (Vaccine Therapy) and Sargramostim Given After Standard of Care Treatment With Rituximab and Chemotherapy for Initial Treatment With Lymphoma

NCT00510471
View directory record Official record
Conditions
Non-Hodgkin's Lymphoma
Interventions
autologous immunoglobulin idiotype-KLH conjugate vaccine
Drug
Lead sponsor
Genitope Corporation
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2007
U.S. locations
9
States / cities
Los Angeles, California • Denver, Colorado • Indianapolis, Indiana + 6 more
Source: ClinicalTrials.gov public record
Updated Mar 18, 2008 · Synced Oct 28, 2026, 6:51 AM EDT
Recruiting Phase 2 Interventional

Antibiotic Prophylaxis to Prevent Obesity-Related Induction Complications in Nulliparae at Term 2.0

NCT06488781
View directory record Official record
Conditions
Obesity in Pregnancy, Labor Complication
Interventions
Azithromycin, Placebo
Drug
Lead sponsor
University of Oklahoma
Other
Eligibility
15 Years to 45 Years · Female only
Enrollment
787 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
1
States / cities
Oklahoma City, Oklahoma
Source: ClinicalTrials.gov public record
Updated Mar 12, 2026 · Synced Oct 28, 2026, 6:51 AM EDT
Withdrawn Not applicable Interventional

Treadmill Training in Chronic MS: Efficacy and Cost-effectiveness

NCT00334100
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Exercise
Behavioral
Lead sponsor
US Department of Veterans Affairs
Federal
Eligibility
Not listed
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2014
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 9, 2014 · Synced Oct 28, 2026, 6:51 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Andes Virus DNA Vaccine for the Prevention of Hantavirus Pulmonary Syndrome Using the PharmaJet Stratis(R) Needle-Free Injection Delivery Device

NCT03682107
View directory record Official record
Conditions
Hantavirus Pulmonary Infection, Immunisation
Interventions
Andes virus DNA vaccine, Placebo
Biological · Other
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 49 Years
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Nov 22, 2022 · Synced Oct 28, 2026, 6:51 AM EDT
Completed Phase 3 Interventional Results available

Study Assessing Dolutegravir in HIV-1 Infected Subjects With Virus Resistant to Raltegravir and/or Elivitegravir

NCT01568892
View directory record Official record
Conditions
HIV Infections
Interventions
Dolutegravir 50 mg twice daily, Dolutegravir placebo twice daily
Drug
Lead sponsor
ViiV Healthcare
Industry
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
25
States / cities
Little Rock, Arkansas • Bakersfield, California • Beverly Hills, California + 21 more
Source: ClinicalTrials.gov public record
Updated Jul 2, 2018 · Synced Oct 28, 2026, 6:51 AM EDT
Active, not recruiting Phase 3 Interventional

Study Comparing Intravenous (IV)/Subcutaneous (SC) Risankizumab to IV/SC Ustekinumab to Assess Change in Crohn's Disease Activity Index (CDAI) in Adult Participants With Moderate to Severe Crohn's Disease (CD)

NCT04524611
View directory record Official record
Conditions
Crohn's Disease (CD)
Interventions
Risankizumab, Ustekinumab
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years to 80 Years
Enrollment
527 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2028
U.S. locations
72
States / cities
Chandler, Arizona • Coronado, California • Irvine, California + 62 more
Source: ClinicalTrials.gov public record
Updated Apr 13, 2026 · Synced Oct 28, 2026, 6:51 AM EDT
Terminated Phase 2 Interventional

To Assess Efficacy and Safety of Batoclimab in Adult Participants With Active CIDP

NCT05581199
View directory record Official record
Conditions
Chronic Inflammatory Demyelinating Polyneuropathy
Interventions
Batoclimab 680 milligrams (mg) subcutaneous (SC) weekly, Batoclimab 340 mg SC weekly, Placebo
Drug
Lead sponsor
Immunovant Sciences GmbH
Industry
Eligibility
18 Years and older
Enrollment
94 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
21
States / cities
Scottsdale, Arizona • Los Angeles, California • Aurora, Colorado + 17 more
Source: ClinicalTrials.gov public record
Updated Aug 11, 2026 · Synced Oct 28, 2026, 6:51 AM EDT
Completed Not applicable Interventional Results available

Cryoanalgesia to Treat Post-Amputation Phantom Limb Pain: A Department of Defense Funded Multicenter Study

NCT03449667
View directory record Official record
Conditions
Post-Amputation Phantom Limb Pain
Interventions
Cryoneurolysis, Sham Comparator
Device
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years and older
Enrollment
144 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
6
States / cities
Palo Alto, California • San Diego, California • Gainesville, Florida + 2 more
Source: ClinicalTrials.gov public record
Updated Feb 17, 2023 · Synced Oct 28, 2026, 6:51 AM EDT
Not yet recruiting Early Phase 1 Interventional Accepts healthy volunteers

tDCS for Cancer-Related Fatigue and Weakness

NCT07159100
View directory record Official record
Conditions
Cancer-related Fatigue, Neuromodulation
Interventions
Active tDCS + elbow flexion exercise, Sham tDCS + elbow flexion exercise
Device · Drug
Lead sponsor
Kessler Foundation
Other
Eligibility
40 Years to 80 Years
Enrollment
75 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2027
U.S. locations
1
States / cities
West Orange, New Jersey
Source: ClinicalTrials.gov public record
Updated Sep 8, 2025 · Synced Oct 28, 2026, 6:51 AM EDT
Completed Not applicable Interventional

Subacute Effects of Spinal Mobilization to Treat Subacromial Impingement

NCT01753271
View directory record Official record
Conditions
Subacromial Impingement Syndrome
Interventions
thoracic mobilization & shoulder mobilization & exercise, shoulder mobilization & exercise
Other
Lead sponsor
High Point University
Other
Eligibility
18 Years to 50 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2012
U.S. locations
3
States / cities
Chicago, Illinois • Elizabethton, Tennessee • Johnson City, Tennessee
Source: ClinicalTrials.gov public record
Updated Aug 20, 2015 · Synced Oct 28, 2026, 6:51 AM EDT
Terminated Phase 2 Interventional Results available

Study to Evaluate the Efficacy and Safety of the Combination of Niraparib and Dostarlimab (TSR-042) in Participants With Platinum Resistant Ovarian Cancer

NCT03955471
View directory record Official record
Conditions
Ovarian Neoplasms
Interventions
Niraparib, Dostarlimab
Drug
Lead sponsor
Tesaro, Inc.
Industry
Eligibility
18 Years and older · Female only
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
27
States / cities
Scottsdale, Arizona • Duarte, California • Newport Beach, California + 22 more
Source: ClinicalTrials.gov public record
Updated Sep 10, 2022 · Synced Oct 28, 2026, 6:51 AM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

More Outside Your Door: a Diet/physical Activity Intervention to Decrease Risk of Obesity in Alaska Native Preschoolers

NCT06303544
View directory record Official record
Conditions
Child Obesity
Interventions
Wedge 1
Behavioral
Lead sponsor
Alaska Native Tribal Health Consortium
Other
Eligibility
3 Years to 5 Years
Enrollment
450 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2028
U.S. locations
1
States / cities
Anchorage, Alaska
Source: ClinicalTrials.gov public record
Updated Jan 29, 2025 · Synced Oct 28, 2026, 6:51 AM EDT
Completed Phase 3 Interventional Results available

Open-Label Extension Study Of Tofacitinib In Psoriatic Arthritis

NCT01976364
View directory record Official record
Conditions
Arthritis, Psoriatic
Interventions
Tofacitinib, Methotrexate, Placebo Methotrexate
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
686 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
43
States / cities
Birmingham, Alabama • Huntsville, Alabama • Glendale, Arizona + 31 more
Source: ClinicalTrials.gov public record
Updated May 21, 2020 · Synced Oct 28, 2026, 6:51 AM EDT
Active, not recruiting Not applicable Interventional Accepts healthy volunteers

Improving Utilization of Lung Cancer Screening in Underserved PA Populations

NCT04806399
View directory record Official record
Conditions
Lung Cancer
Interventions
Educational Materials and Decision Counseling
Other
Lead sponsor
American College of Radiology
Other
Eligibility
50 Years to 77 Years
Enrollment
2,500 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
2
States / cities
Allentown, Pennsylvania • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 15, 2024 · Synced Oct 28, 2026, 6:51 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Family Relationships and Nutrition in TGGD Youth and Young Adults

NCT05163860
View directory record Official record
Conditions
Family Relations, Nutrition Disorders, Health Behavior, Transgenderism
Interventions
Survey
Other
Lead sponsor
St. Louis University
Other
Eligibility
12 Years and older
Enrollment
714 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Mar 9, 2022 · Synced Oct 28, 2026, 6:51 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Physical and Social Environmental Influence on Children's Exercise: Preparation (Pre-PLACE)

NCT03087123
View directory record Official record
Conditions
Physical Activity
Interventions
P-Mobile App
Behavioral
Lead sponsor
Pennington Biomedical Research Center
Other
Eligibility
6 Years to 10 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2019
U.S. locations
1
States / cities
Baton Rouge, Louisiana
Source: ClinicalTrials.gov public record
Updated Sep 28, 2022 · Synced Oct 28, 2026, 6:51 AM EDT
Completed Not applicable Interventional

Cognitive Behavioral Therapy (CBT) Study Evaluating the Updating of Persecutory Beliefs

NCT04748679
View directory record Official record
Conditions
Schizophrenia; Psychosis, Persecutory Delusion
Interventions
Worry Intervention, Befriending
Behavioral
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
18 Years to 65 Years
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Aug 15, 2024 · Synced Oct 28, 2026, 6:51 AM EDT
Recruiting Phase 2 Interventional

Cobimetinib in Refractory Langerhans Cell Histiocytosis (LCH), and Other Histiocytic Disorders

NCT04079179
View directory record Official record
Conditions
Langerhan's Cell Histiocytosis, Juvenile Xanthogranuloma, Erdheim-Chester Disease, Rosai Dorfman Disease, Neuro-Degenerative Disease, Histiocytic Sarcoma, Histiocytic Disorders, Malignant
Interventions
Cobimetinib
Drug
Lead sponsor
Carl Allen
Other
Eligibility
Not listed
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2029
U.S. locations
12
States / cities
Phoenix, Arizona • Little Rock, Arkansas • Orange, California + 9 more
Source: ClinicalTrials.gov public record
Updated Oct 26, 2026 · Synced Oct 28, 2026, 6:51 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Neurophysiological Effects on tPCS and tDCS on Healthy Subjects and on Patients With Chronic Visceral Pain

NCT02497196
View directory record Official record
Conditions
Visceral Pain, Pancreatitis, Pelvic Pain
Interventions
Active tPCS, Active tDCS, Sham tPCS, Sham tDCS
Device
Lead sponsor
Spaulding Rehabilitation Hospital
Other
Eligibility
18 Years to 60 Years
Enrollment
54 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
1
States / cities
Charlestown, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 24, 2020 · Synced Oct 28, 2026, 6:51 AM EDT
Active, not recruiting Phase 2 Interventional

Ph1b/2 Study of the Safety and Efficacy of T-DXd Combinations in Advanced HER2-expressing Gastric Cancer (DESTINY-Gastric03)

NCT04379596
View directory record Official record
Conditions
Gastric Cancer
Interventions
Fluorouracil (5-FU), Capecitabine, Durvalumab, Oxaliplatin, Trastuzumab, Trastuzumab deruxtecan, Cisplatin, Pembrolizumab, Volrustomig, Rilvegostomig
Drug · Biological
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 130 Years
Enrollment
452 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
4
States / cities
Baltimore, Maryland • Boston, Massachusetts • New York, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Aug 28, 2026 · Synced Oct 28, 2026, 6:51 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Preventing Sexual Aggression Among High School Boys

NCT02506088
View directory record Official record
Conditions
Violence
Interventions
Your Voice Your View
Behavioral
Lead sponsor
Lifespan
Other
Eligibility
Not listed
Enrollment
7,910 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2018
U.S. locations
1
States / cities
Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated Oct 31, 2018 · Synced Oct 28, 2026, 6:51 AM EDT
Completed Phase 2 Interventional Results available

ADVM-022 Intravitreal Gene Therapy for DME

NCT04418427
View directory record Official record
Conditions
Diabetic Macular Edema, Diabetic Retinopathy
Interventions
6E11 vg/eye of ADVM-022, 2E11 vg/eye of ADVM-022, Aflibercept
Biological
Lead sponsor
Adverum Biotechnologies, Inc.
Industry
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
13
States / cities
Phoenix, Arizona • Bakersfield, California • Beverly Hills, California + 10 more
Source: ClinicalTrials.gov public record
Updated Jul 10, 2025 · Synced Oct 28, 2026, 6:51 AM EDT